GPR89 Activators
GPR89 Activators are a specific selection of chemical compounds that influence the functional activity of GPR89 through indirect mechanisms tied to signaling pathways this protein is associated with. Forskolin, IBMX, Isoproterenol, PGE2, Rolipram, Zaprinast, Adenosine, BAY 60-6583, Vardenafil, Anagrelide, and Fenoldopam all play a role in increasing intracellular cyclic AMP (cAMP) levels, either by direct activation of adenylate cyclase, inhibition of cAMP-degrading phosphodiesterases, or activating cAMP-related G-protein-coupled receptors. The enhanced cAMP levels in turn activate PKA or other cAMP-dependent pathways, leading to the phosphorylation of downstream substrates that could include GPR89 or its associated signaling partners, thereby potentially amplifying its signaling capacity.
In addition to the cyclic nucleotide pathway modulators, A23187 (Calcimycin) serves as an ionophore that elevates intracellular calcium levels, which can initiate a cascade of calcium-dependent signaling events. These events may intersect with GPR89-related pathways, thus influencing the protein's activity. The combined effects of these GPR89 Activators, through their targeted regulation of intracellular messenger systems, create an environment conducive to the enhanced activity of GPR89. This synergy of biochemical actionsI apologize for the oversight.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases (PDEs) which increases intracellular cAMP levels by preventing its degradation. This indirect action can potentiate the cAMP-dependent pathway that GPR89 is a part of, leading to its enhanced activity. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G-protein-coupled receptors, potentially leading to increased intracellular cAMP. This action could amplify signaling mechanisms that involve GPR89. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of PDE4, an enzyme that degrades cAMP. By inhibiting PDE4, rolipram raises cAMP levels, which may indirectly activate GPR89 by strengthening cAMP-dependent signaling. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of PDE5, which also increases cAMP levels in cells. The elevation of cAMP may in turn enhance GPR89 activity by engaging relevant signaling pathways. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine interacts with its receptors, which can increase cAMP production. This increase in cAMP might indirectly activate GPR89 by intensifying the associated signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. The change in calcium dynamics could affect pathways that are linked to GPR89 function, indirectly enhancing its activity. | ||||||
BAY 60-6583 | 910487-58-0 | sc-503262 | 10 mg | $210.00 | ||
BAY 60-6583 is a selective adenosine A2B receptor agonist, promoting cAMP accumulation. This could indirectly enhance GPR89 function if GPR89 is coupled to cAMP-mediated signaling. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil is a selective inhibitor of PDE5, leading to increased cAMP and cGMP levels. The rise in cyclic nucleotides may indirectly enhance GPR89 signaling pathways associated with these molecules. | ||||||